WESTON, Mass.–(BUSINESS WIRE)–Aquyre Biosciences, Inc. today announced the appointment of Gregory Bowles as President, Chief Executive Officer and member of the Board of Directors. This evolution in leadership aims to take the company to the next stage with the development and launch of the Van Gogh system, an advanced phase-contrast microscope that is optimized for “specimen adequacy assessment”, a critical step in cancer diagnosis.
Greg has over 20 years of experience in the medical technologies industry. During his career, Greg and has played an instrumental role in several startups. At Intuitive Surgical during its early years, he was the Capital Sales Manager where he sold the daVinci Robot in Michigan. Greg’s first startup was EndoGastric Solutions where he held positions as Regional Manager and later as Vice President of Sales. At EndoGastric Solutions, Greg’s leadership was instrumental resulting in significant revenue growth. In 2013, Greg became a co-founder and co-inventor at FlexDex Surgical, a University of Michigan startup. Initially serving as General Manager and later as Chief Marketing Officer, Greg was responsible for the development and implementation of the Company’s marketing and sales strategy. While at Aquyre Biosciences, Greg was the Senior Vice President of Sales and Marketing and has been instrumental in building the company’s commercialization efforts. This includes the clinical validation of Aquyre’s proprietary technology through the successful completion of clinical studies and market validation with product sales to community and academic hospitals in the U.S. Previous to his industry experience, Greg served in the U.S. Navy and National Security Agency as a cryptologist for 15 years where he managed government programs and coordinated activities with foreign agencies to support operations worldwide.
Aquyre is ready for its next growth phase. “In the past 2 years, our CelTivity system has been used in over 800 lung procedures for specimen adequacy assessment and the detection of cancer,” said Greg. “In these procedures, we have observed and measured significant improvements in patient care, including shorter procedure times, higher diagnostic yield and fewer biopsies taken. Our new system, Van Gogh, will launch in early 2024 and enable Aquyre to expand manufacturing to meet the increasing demand in the market. While the Van Gogh system can be used for biopsy adequacy assessment as a critical part of the diagnosis of various type of cancer, Aquyre’s initial focus will be on lung cancer. In the United States, there are over 1.5 million patients with lung nodules identified and evaluated each year. It’s a privilege to lead our amazingly talented team as we prepare to bring a new level of precision microscopy to specimen adequacy assessment, improve the physician’s ability to identify cancer and potentially improve patient care worldwide.”
About Aquyre Biosciences
Aquyre Biosciences, Inc is the creator of CelTivity™, the industry leader in rapid digital specimen adequacy assessment. Powered by Dynamic Cell Imaging™ (DCI), CelTivity scans a biopsy, images the cells and measures the intracellular and metabolic activity. This activity is presented as a cellular heatmap, making analysis and the detection of cancer, granuloma, and immune cells such as lymphocytes relatively easier than traditional cancer diagnostic methods. The assessment does not require any cutting or staining, meaning the same specimen assessed for adequacy can go to pathology for final diagnosis. Aquyre Biosciences is headquartered in Weston, Mass. For more information, please visit www.aquyre.com
